Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 601 to 650 of 2564

TitleReference numberPublishedLast updated
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)TA842
Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodulesHTG646
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)TA840
Extracorporeal shockwave therapy for calcific tendinopathy in the shoulderHTG645
Advocacy services for adults with health and social care needsNG227
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838
Digital technologies for the detection of melanomaMIB311
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraineHTG643
YAG laser vitreolysis for symptomatic vitreous floatersHTG644
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Osteoarthritis in over 16sQS87
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Osteoarthritis in over 16s: diagnosis and managementNG226
O2matic PRO 100 for optimising oxygen treatment in respiratory conditionsMIB308
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerHTG642
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Signatera for detecting molecular residual disease from solid tumour cancersMIB307
Upadacitinib for treating active ankylosing spondylitisTA829
Postnatal careQS37
Neurostimulation of lumbar muscles for refractory non-specific chronic low back painHTG641
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasiaMIB306
Neuropad for detecting preclinical diabetic peripheral neuropathyHTG486
Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasiaHTG639
Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopauseHTG640
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Self‑harmQS34
Self-harm: assessment, management and preventing recurrenceNG225
Faecal microbiota transplant for recurrent Clostridioides difficile infectionHTG638
Brolucizumab for treating diabetic macular oedemaTA820
Contrast-enhanced spectral mammography for breast cancerMIB304
Differential target multiplexed spinal cord stimulation for chronic lower back and leg painMIB305
iFuse for treating chronic sacroiliac joint painHTG488
Focal resurfacing implants to treat articular cartilage damage in the kneeHTG635
Transcutaneous electrical neuromuscular stimulation for urinary incontinenceHTG636
Superficial venous arterialisation for chronic limb threatening ischaemiaHTG637
Avalglucosidase alfa for treating Pompe diseaseTA821
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsAMR1
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsAMR2
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Type 1 diabetes in adults: diagnosis and managementNG17

Results per page

  1. 10
  2. 25
  3. 50
  4. All